Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

GOSS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Gossamer Bio, Inc.NASDAQ: GOSS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $46.66M (cash outflow) rose 27.4% year over year, behind the +252.1% change in trailing-twelve-month net income. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.

Context

  • Net income amounted to 351.5% of revenue in FY2025, up 302.2 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$93.3M (-45.2%) for the fiscal year ending Dec 2026, a slowdown from the +201.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$46.66M-1.2% QoQ
Last fiscal yearDec 2025
-$170.37M+201.4% YoY
LTMMar 2026
-$180.4M+252.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.4%+68.5%+41.1 pp
1 year+201.4%-45.2%-246.6 pp
3-year CAGR-9.4%-58.1%-48.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(170.37M) USD
Year-over-year change
-201.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 net income of $180.4M is the 4th largest of the 9 companies compared; the peer median is $144.81M.
  • Its year-over-year change of +252.1% is the 2nd highest of 8, against a peer median of +37.1%.
  • Net income amounts to 324.8% of revenue for GOSS, versus a peer median of 151.9%.
GOSS Competitors Peer median
Net Income for GOSS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$364.23M +879.7%—121.5%
RGNXREGENXBIO Inc.LTM Mar 2026$290.01M +83.9%-11.6%330.2%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$185.15M +43.6%+15.7%—
GOSSGossamer Bio, Inc.LTM Mar 2026$180.4M +252.1%-9.4%324.8%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$160.9M -8.8%+9.2%182.3%
PRTAProthena Corporation plcLTM Mar 2026$151.18M +37.1%+27.8%260.9%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$138.44M ——119.4%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$44.17M +6.7%-28.2%—
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$26.09M -85.3%-21.0%37.5%
Peer median (excluding GOSS) $144.81M+37.1%-1.2%151.9%

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
Deferred Income Tax00000
Stock-Based Compensation32.01M42.55M28.52M20.62M10.56M
Change in Working Capital774K(4.46M)(14.84M)39.46M(13.63M)
Accounts Receivables000(5.34M)(6.89M)
Inventory00000
Accounts Payables(4.43M)(1.81M)3.99M(1.66M)(2.75M)
Other Working Capital5.2M(2.65M)(18.83M)46.45M(3.99M)
Other Non-Cash Items7.17M(177K)2.6M(11.17M)1.18M
Operating Cash Flow(188.89M)(187.03M)(159.16M)(3.47M)(171.27M)
Capital Expenditures(1.62M)(475K)00(79K)
Acquisitions (Net)0(65K)000
Purchases of Investments(152.03M)(238.06M)(441.67M)(494.78M)(227.11M)
Sales of Investments36.23M237.5M330.7M523.8M383.54M
Other Investing Activities(75K)65K000
Investing Cash Flow(117.43M)(1.04M)(110.97M)29.02M156.36M
Debt Repayment0(5.81M)(11.61M)(12.58M)0
Common Stock Issued0119.95M201.32M464K6.43M
Common Stock Repurchased000629K0
Dividends Paid00000
Other Financing Activities3.33M2.95M444K00
Financing Cash Flow3.33M117.09M190.15M(11.49M)6.43M
Effect of Forex Changes(165K)(517K)110K(102K)141K
Net Change in Cash(303.15M)(71.49M)(79.86M)13.97M(8.34M)
Free Cash Flow(190.51M)(187.51M)(159.16M)(3.47M)(171.35M)

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.